Trial Profile
A Phase I, Multicenter, Open-label, Dose Escalation Study of Intravenous Administration of VCN-01 Oncolytic Adenovirus With or Without Gemcitabine and Abraxane in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; VCN 01 (Primary)
- Indications Adenocarcinoma; Gastrointestinal stromal tumours; Head and neck cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Theriva Biologics
- 28 Mar 2022 Results published in the Synthetic Biologics Media Release.
- 28 Mar 2022 According to a Synthetic Biologics media release, data from this trial were published in the Journal for ImmunoTherapy of Cancer.
- 07 Oct 2020 Status changed from active, no longer recruiting to completed.